amyloid Archives -

FDA blocks early nod for Lilly’s Alzheimer’s drug donanemab

Phil Taylor Alzheimer's disease, amyloid, Biogen, donanemab, Eisai, Eli Lilly, Leqembi, regulatory 0 Comment

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer’s disease therapy donanemab

FDA blocks early nod for Lilly’s Alzheimer’s drug donanemab

https://pharmaphorum.com/news/fda-blocks-early-nod-for-lillys-alzheimers-drug-donanemab/

News/ News/ R&D

Alzheimer’s treatment hopes take another dive as Roche drug fails trial

Phil Taylor Alzheimer's disease, amyloid, Biogen, Eisai, gantenerumab, Genentech, lecanemab, neurology, Roche 0 Comment

Roche’s Genentech division has reported disappointing top-line results from its highly-anticipated phase 3 trial of gantenerumab in early

Alzheimer’s treatment hopes take another dive as Roche drug fails trial

https://pharmaphorum.com/news/alzheimers-treatment-hopes-take-another-dive-as-roche-drug-fails-trial/

News/ News/ R&D

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

Phil Taylor AC Immune, Alzheimer's disease, amyloid, crenezumab, gantenerumab, Genentech, Roche 0 Comment

The litany of failed trials of amyloid-targeting drugs for Alzheimer’s disease has added another verse, as Roche concedes

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

https://pharmaphorum.com/news/another-amyloid-miss-in-alzheimers-as-roches-crenezumab-fails-trial/

Market Access/ News/ News

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

Phil Taylor Aduhelm, Alzheimer's disease, amyloid, Biogen, Eisai, lecanemab, regulatory 0 Comment

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

https://pharmaphorum.com/news/exit-aduhelm-enter-lecanemab-biogen-and-eisai-have-another-go/

News/ News/ Sales and Marketing

CMS decision on Aduhelm is in, and it’s bad news for Biogen

Phil Taylor Aduhelm, Alzheimer's disease, amyloid, Biogen, Medicare 0 Comment

The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement

CMS decision on Aduhelm is in, and it’s bad news for Biogen

https://pharmaphorum.com/news/cms-decision-on-aduhelm-is-in-and-its-bad-news-for-biogen/

News/ News/ R&D

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

Phil Taylor Alzheimer's disease, amyloid, antibody, Bristol-Myers Squibb, donanemab, Eli Lilly, neurology, Prothena, Tau 0 Comment

Just a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

https://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/

Market Access/ News/ News

Double resignation over Aduhelm approval depletes FDA’s CNS adcomm

Phil Taylor aducanumab, Aduhelm, Alzheimer's, amyloid, Biogen, central nervous system, fda, neurology, regulatory 0 Comment

Two members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s

Double resignation over Aduhelm approval depletes FDA’s CNS adcomm

https://pharmaphorum.com/news/double-resignation-over-aduhelm-approval-depletes-fdas-cns-adcomm/

Market Access/ News/ News

Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, amyloid, Biogen, fda, neurology 0 Comment

Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab

Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab

https://pharmaphorum.com/news/jubilation-at-biogen-as-fda-says-yes-to-aducanumab/

News/ News/ R&D

Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

Phil Taylor aducanumab, Alzheimer's disease, amyloid, Biogen, donanemab, Eisai, Eli Lilly, neurology 0 Comment

When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a

Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/

Trending

amyloid

Login